基于潜在类别分析的不同CD73多发性骨髓瘤患者预后复发的影响因素分布特征研究

doi:10.11904/j.issn.1002-3070.2022.04.008

实用肿瘤学杂志 ›› 2022, Vol. 36 ›› Issue (4): 332-338.doi: 10.11904/j.issn.1002-3070.2022.04.008

基于潜在类别分析的不同CD73多发性骨髓瘤患者预后复发的影响因素分布特征研究

徐娟¹, 贲海祥¹, 丁琳琳¹, 蔡亚云¹, 陈婷¹, 姜铭²

1.如皋市人民医院血液科(如皋 226500);
2.如皋市人民医院检验科

收稿日期:2022-03-04 修回日期:2022-06-20 出版日期:2022-08-28 发布日期:2022-08-29
通讯作者: 徐娟,E-mail:banque46290@163.com
作者简介:徐娟,女,(1977-),本科,副主任医师,从事多发性骨髓瘤、骨髓增生异常综合征的相关研究。

Analysis of the distribution characteristics of influencing factors for prognosis and recurrence of different CD73 multiple myeloma patients based on latent class

XU Juan¹, BEN Haixiang¹, DING Linlin¹, CAI Yayun¹, CHEN Ting¹, JIANG Ming²

1. Department of Hematology,Rugao People's Hospital,Rugao 226500,China;
2. Department of Clinical Laboratory,Rugao People's Hospital

Received:2022-03-04 Revised:2022-06-20 Online:2022-08-28 Published:2022-08-29

摘要/Abstract

摘要： 目的探究多发性骨髓瘤(MM)患者复发的影响因素,并分析不同CD73⁺表达率患者复发影响因素的分布特征。方法选择2017年2月—2021年2月我院收治的108例MM患者作为研究对象,根据治疗后1年的复发情况分为复发组和未复发组。筛选影响患者复发的因素;采用聚类分析和潜在类别分析方法分析不同CD73患者复发影响因素的分布特征。结果 108例患者的复发率为23.15%(25/108);男性、体质指数(BMI)＜20 kg/m²、国际分期系统(ISS)分期Ⅲ期、高危遗传学风险、β2-微球蛋白(β2-MG)≥3.5 mg/L、p53基因缺失、CD73⁺均是导致患者复发的危险因素(P＜0.05),维持治疗是保护因素(P＜0.05)。聚类分析结果显示,复发风险呈明显聚集性,可将患者分为复发高风险组(CD73⁺表达率＞40%)和低风险组(CD73⁺表达率＜40%),复发率分别为37.50%(15/40)和14.71%(10/68),差异具有统计学意义(P＜0.05);潜在类别分析结果显示,复发高风险组“危险因素较少型分布”比例明显低于复发低风险组,“ISS分期Ⅲ期未维持治疗分布”比例明显高于复发低风险组(P＜0.05),两组“ISS分期Ⅲ期维持治疗分布”比例差异无统计学意义(P＞0.05)。结论性别、BMI、ISS分期等因素均与MM患者复发相关;CD73⁺表达率＞40%的患者复发风险较高,影响因素主要为“ISS分期Ⅲ期未维持治疗分布”。

关键词: CD73, 多发性骨髓瘤, 复发, 影响因素, 潜在类别分析

Abstract: Objective The aim of this study was to explore the influencing factors of recurrence in patients with multiple myeloma(MM),and to analyze the distribution characteristics of factors affected recurrence in patients with different CD73⁺ expression rates.Methods A total of 108 patients with MM who were treated in our hospital from February 2017 to February 2021 were selected as the research subjects,and they were divided into a recurrence group and a non-recurrence group according to the recurrence one year after treatment.The factors affected the recurrence of patients were screened;cluster analysis and latent class were used to analyze the distribution characteristics of the factors affecting the recurrence different CD73 patients.Results The recurrence rate of 108 patients was 23.15%(25/108).Male,body mass index(BMI)＜20 kg/m²,international staging system(ISS)stage Ⅲ,high-risk genetic risk,β2-microglobulin(β2-MG)≥3.5 mg/L,p53 gene deletion,and CD73⁺ were independent risk factors for relapse(P＜0.05).Maintenance therapy was a protective factor(P＜0.05).The results of cluster analysis showed that the recurrence risk was obviously clustered,and the patients could be divided into a high-risk group(the expression rate of CD73⁺＞40%)and a low-risk group(the expression rate of CD73⁺＜40%),with a recurrence rates of 37.50%(15/40)and 14.71%(10/68),the difference was statistically significant(P＜0.05).The results of latent class analysis showed that the proportion of patients with “less risk factor distribution” in the high-risk group for recurrence was significantly lower than that in the low-risk group for recurrence,and the proportion of patients with “distribution for ISS stage Ⅲ without maintenance treatment” was significantly higher than that in the low-risk group for recurrence(P＜0.05),there was no significant difference in the proportion of patients in the “ISS stage Ⅲ maintenance treatment distribution” between the two groups(P＞0.05).Conclusion Gender,BMI,ISS stage and other factors are related to the recurrence of MM patients.Patients with ＞40% of CD73⁺ expression rate have a higher risk of recurrence,and the main influencing factor is “ISS stage Ⅲ without maintenance treatment distribution”.

Key words: CD73, Multiple myeloma, Recrudescence, Influencing factors, Latent class analysis

中图分类号:

R733.3

徐娟, 贲海祥, 丁琳琳, 蔡亚云, 陈婷, 姜铭. 基于潜在类别分析的不同CD73多发性骨髓瘤患者预后复发的影响因素分布特征研究[J]. 实用肿瘤学杂志, 2022, 36(4): 332-338.

XU Juan, BEN Haixiang, DING Linlin, CAI Yayun, CHEN Ting, JIANG Ming. Analysis of the distribution characteristics of influencing factors for prognosis and recurrence of different CD73 multiple myeloma patients based on latent class[J]. Journal of Practical Oncology, 2022, 36(4): 332-338.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2022.04.008

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2022/V36/I4/332

参考文献

1 刘希洋,张红梅,宋永平,等.以肺部占位为首发症状的多发性骨髓瘤1例及文献复习[J].肿瘤学杂志,2020,26(4):368-370.
2 李玉军,刘丽洋,肖娟娟.新诊断老年多发性骨髓瘤的预后分层及治疗进展[J].实用肿瘤学杂志,2022,36(1):84-88.
3 Wu Z,Zhang Y,Yang Z,et al.Elevation of miR-302b prevents multiple myeloma cell growth and bone destruction by blocking DKK1 secretion[J].Cancer Cell Int,2021,21(1):187-199.
4 Spaan I,Stolpe A,Raymakers RA,et al.Multiple myeloma relapse is associated with increased NFκB pathway activity and upregulation of the pro-survival BCL-2 protein BFL-1[J].Cancers(Basel),2021,13(18):4668-4683.
5 Díaz-Tejedor A,Lorenzo-Mohamed M,Puig N,et al.Immune system alterations in multiple myeloma:molecular mechanisms and therapeutic strategies to reverse immunosuppression[J].Cancers(Basel),2021,13(6):1353-1378.
6 Chen Q,Pu N,Yin H,et al.CD73 acts as a prognostic biomarker and promotes progression and immune escape in pancreatic cancer[J].J Cell Mol Med,2020,24(15):8674-8686.
7 Yang R,Elsaadi S,Misund K,et al.Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade[J].J Immunother Cancer,2020,8(1):610-623.
8 中国医师协会血液科医师分会,中华医学会血液学分会,中国医师协会多发性骨髓瘤专业委员会.中国多发性骨髓瘤诊治指南(2020年修订)[J].中华内科杂志,2020,59(5):341-346.
9 Garcés JJ,Bretones G,Burgos L,et al.Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma[J].Leukemia,2020,34(11):3007-3018.
10 Pourmoussa AM,Spielberger R,Cai J,et al.Predictive factors for early relapse in multiple myeloma after autologous hematopoietic stem cell transplant[J].Perm J,2019,23:19.
11 暴江萍,苏丽萍,张凤华,等.硼替佐米联合自体造血干细胞移植治疗多发性骨髓瘤预后不良的影响因素[J].中国实用医刊,2020,47(21):56-59.
12 Hofbauer D,Mougiakakos D,Broggini L,et al.β2-microglobulin triggers NLRP3 inflammasome activation in tumor-associated macrophages to promote multiple myeloma progression[J].Immunity,2021,54(8):1772-1787.
13 Drozdkova DH,Gursky J,Minarik J,et al.CDKN1A gene expression in two multiple myeloma cell lines with different p53 functionality[J].Anticancer Res,2020,40(9):4979-4987.
14 李青,胡赤丁,张长春,等.初诊IgG水平对IgG型多发性骨髓瘤患者初治完全缓解后复发的预测价值[J].中国实验血液学杂志,2021,29(6):1825-1830.

[1]	李玉军, 刘丽洋, 肖娟娟, 薛华. 新诊断老年多发性骨髓瘤的预后分层及治疗进展[J]. 实用肿瘤学杂志, 2022, 36(1): 84-88.
[2]	穆慧娟, 李海娜, 吕艺, 孙丽华, 王丽娟, 礼彦侠, 于飞, 潘国伟, 刘莉. 辽宁省三城市居民胃癌10年生存率及其影响因素分析[J]. 实用肿瘤学杂志, 2021, 35(4): 339-343.
[3]	董晓平, 张雪, 郭冬利, 贺宇彤. 肺鳞状细胞癌预后相关影响因素研究进展[J]. 实用肿瘤学杂志, 2021, 35(4): 380-385.
[4]	秦伟, 何义富, 常娜, 钱立庭, 黄大兵, 崔亚云. 局部晚期宫颈癌放射治疗对直肠功能影响的研究进展[J]. 实用肿瘤学杂志, 2021, 35(2): 170-173.
[5]	徐志勇,马晓良. 甲状腺癌患者术后复发风险预测的列线图模型建立[J]. 实用肿瘤学杂志, 2021, 35(1): 35-40.
[6]	党瑶,皇甫辉,秦艺骁,车琴,郝晓龙(综述),王斌全(审校). 头颈部鳞状细胞癌转移机制及其影响因素研究进展[J]. 实用肿瘤学杂志, 2021, 35(1): 78-82.
[7]	赵颖欣, 秦玲. 二甲双胍与多发性骨髓瘤的研究进展[J]. 实用肿瘤学杂志, 2020, 34(5): 476-479.
[8]	王鹏, 张玉宝. 胰十二指肠切除术后胰瘘的影响因素研究进展[J]. 实用肿瘤学杂志, 2020, 34(1): 64-68.
[9]	李剑, 徐向英, 吕研. 局限期小细胞肺癌首程治疗失败后再程治疗的相关研究[J]. 实用肿瘤学杂志, 2019, 33(6): 519-524.
[10]	李嘉琪,栾瑾微,张,玉,李香兰. 763例三阴性乳腺癌临床病理特征及复发、转移影响因素分析[J]. 实用肿瘤学杂志, 2019, 33(3): 244-249.
[11]	马志杰, 王帆, 赵亚双. 乳腺癌化疗患者生存质量及影响因素分析[J]. 实用肿瘤学杂志, 2019, 33(2): 149-154.
[12]	赵凤娟, 王琪, 任贇虹, 韦珏伶, 黎乐群, 赵新华, 唐娟, 游雪梅. 肝癌伴抑郁患者血清CRP、hs-CRP水平变化及其对预后的影响[J]. 实用肿瘤学杂志, 2019, 33(1): 27-33.
[13]	张攀, 张迪综述, 戴晓波审校. 复发鼻咽癌再程放射治疗的研究进展[J]. 实用肿瘤学杂志, 2019, 33(1): 92-96.
[14]	王鹏, 周海涛, 梁建伟, 周志祥. 肠系膜纤维瘤病误诊为早期直肠癌根治术后复发1例报道及文献复习[J]. 实用肿瘤学杂志, 2018, 32(5): 442-444.
[15]	刘玉, 王子安. 原发性胃肠道恶性淋巴瘤术后生存期的影响因素及TNM分期对远期生存的预测价值分析[J]. 实用肿瘤学杂志, 2018, 32(4): 315-319.

基于潜在类别分析的不同CD73多发性骨髓瘤患者预后复发的影响因素分布特征研究

Analysis of the distribution characteristics of influencing factors for prognosis and recurrence of different CD73 multiple myeloma patients based on latent class

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价